Novo Nordisk to invest $2.3 billion in French facility to address GLP-1 drug shortage
Manufacturing for the diabetes and weight-loss drugs Ozempic and Wegovy is expected to increase with a billion-dollar investment Novo Nordisk production site located in Chartres, France.
Danish pharmaceutical giant Novo Nordisk announces a $2.3 billion investment into its Chartres, France manufacturing site to boost production of weight-loss and diabetes drugs such as Wegovy and Ozempic, among others.
A growing supply crisis of semaglutide drug products has European healthcare systems worried. The off-label use of Ozempic as an obesity treatment. Ozempic in particular has faced supply shortages in Europe because of its popularity in weight-loss treatment, while Wegovy is not yet widely available in Europe. Some nations are considering bans on off-label prescriptions for Ozempic; Germany has considered banning exports of the drug, while Belgium banned non-diabetes related prescriptions of Ozempic. Novo Nordisk itself has introduced rations for Ozempic starter kits in response to increased demand for weight-loss treatments. Earlier in November 2023, Novo Nordisk announced an increase in investment to $6 billion for production within Denmark.
Estimate analysis of the obesity drug market shows a potential worth of $100 billion by 2030. The investment into the French manufacturing plant will also serve as a boost for France’s economy as it faces a global economic slowdown. During the ‘Choose France’ summit earlier in the year, the office of French President Emmanuel Macron announced they had convinced Novo Nordisk CEO Lars Fruergaard Jorgensen to invest in the French manufacturing site. However, Novo Nordisk has yet to comment on this.
The investment will significantly increase the several types of manufacturing required for the production of GLP-1 drug class, with specialist operations for the filling of injection pens with the API semaglutide. Assembly and packaging operations of the injection pens will also be increased.
Source: Novo Nordisk invests $2.3 billion in France to boost obesity drug production [Accessed November 29, 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-invests-23-mln-france-boost-output-2023-11-23/
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance